Group 1: Bridget Dabanka, Valeriya Lukonen, Rashaun Hill
Economics for Public Administration
Dec 20th, 2023
Prof. Vishal Trehan

Medication Guides: Impact Analysis Case Study

Background

In the evolving landscape of healthcare, persistent barriers impede individuals from accessing the quality care and treatment they rightfully deserve. The FDA's impact analysis, titled "Medication Guides: Patient Medication Information," meticulously delineates studies conducted by professionals to analyze the repercussions of medication adherence and nonadherence on patients and their well-being. Notably, the analysis underscores that "328 studies indicated that the average percent of adherence across studies of medication treatment regimens was 79.4%" (DiMatteo, 2004). This emphasizes that a substantial proportion of patients, 79.4%, dutifully adhere to prescribed medical advice and regimens that their healthcare provider prescribes. Nevertheless, this statistic raises a pertinent question: what about the rest who do not adhere to their medication? How could this be affecting their lifestyle?

The complexity of drug information, coupled with variations in formulations and dosages, poses a significant challenge in ensuring that patients receive standardized, clear, and comprehensive information about their medication. The need for intervention in the PMI landscape is imperative to bridge the informational gap between healthcare providers and patients. The absence of standardized PMI poses a risk to patient safety and undermines the efficacy of medication adherence. Patients, being the end-users of prescribed medications, require accurate, understandable information to make informed decisions about their health. With the complexities of modern drug therapies and the diversity of outpatient prescription products, an intervention becomes essential to ensure that patients receive consistent and comprehensive PMI, ultimately enhancing their ability to manage and understand their medications effectively. The need for intervention is rooted in the overarching goal of improving patient outcomes, fostering a safer healthcare environment, and promoting better-informed patient decision-making.

Nonadherence to medication profoundly affects patients' lives as they navigate imperative instructions from their healthcare providers to treat their health effectively. This phenomenon may stem from a lack of comprehensive understanding or fear of potential side effects associated with prescribed medication. The ramifications of nonadherence extend beyond the individual patients, impacting various stakeholders, including healthcare providers, pharmaceutical companies, and medical insurance companies. Healthcare providers grapple with concerns related to decreased treatment consistency and the effectiveness of prescribed medications. Pharmaceutical companies face diminished profits due to lower demand resulting from decreased medication purchases. The pharmaceutical market, entrenched in a principal-agent structure and third-party payer dynamic, hinges on a delicate balance of transactions, influencing profits for all involved parties. If patients were to contribute more to the cost of their medication, it could reshape the market landscape, potentially limiting patient access to affordable medication and, consequently, hindering their pursuit of improved health and well-being.

The proposed rule in response to this impact analysis asserts that "all human prescription drugs are used, dispensed, or administered on an outpatient basis, including blood components transfused in an outpatient setting" (FDA, 2019). This rule aims to ensure that all patients remain well-informed and possess documented information about the drugs they are prescribed. Medication guides play a crucial role in furnishing essential instructions for individuals to follow when consuming prescribed medications, facilitating the prevention of serious health-related consequences in the long run. The FDA estimates that "PMI reading would save an individual between two and three minutes each time he reads the entire document, with a primary estimate of 2.5 minutes saved." This underscores that Patient Medication Information (PMI) reading not only provides patients with valuable information but also empowers them to actively engage in the healthcare system.

The identification of market failure within the context of PMI arises primarily from the inherent challenges related to the readability and consistency of information provided to patients. The pharmaceutical market, governed by profit motives and competitive dynamics, may inadvertently neglect the imperative of delivering comprehensible and consistent information across online platforms and prescription pamphlets. In a market-driven healthcare system, pharmaceutical manufacturers may prioritize regulatory compliance over ensuring that the information is presented in a manner that is easily understandable for a diverse patient population. Furthermore, the varying formats, such as pamphlets and online resources, contribute to inconsistency in the information presented. This lack of standardization in content and presentation may result from a fragmented approach where individual pharmaceutical companies, driven by competition and differing marketing strategies, produce materials that may not align in clarity and content. Consequently, patients, who are often dealing with complex health conditions, may encounter difficulties in deciphering crucial information about their prescribed medications. This market failure, marked by a lack of readability and consistency, necessitates government intervention to establish standardized guidelines, ensuring that medical information is not only legally compliant but also comprehensible and uniform across various formats, promoting patient understanding and safety.

Stakeholders

The PMI has multifaceted implications for various stakeholders and interest groups across the healthcare landscape. Patients stand to benefit significantly as the primary recipients of improved, standardized drug information, potentially leading to better adherence and health outcomes. However, concerns may arise regarding the readability and comprehensibility of the PMI and the potential for changes in prescription drug costs. Healthcare providers, including doctors, pharmacists, and nurses, will be directly impacted by the rule, necessitating additional responsibilities in explaining and disseminating PMI. The healthcare industry associations, representing a spectrum of stakeholders, are likely to express varying degrees of support or opposition, with pharmaceutical manufacturers possibly facing increased costs for compliance and adjustments to existing Medication Guides or Patient Package Inserts. Insurance companies and payers may be concerned about potential changes in drug pricing and their impact on costs, while pharmacy chains and independent pharmacies could face operational changes and training requirements. The intricate web of stakeholder interests underscores the complexity of implementing the proposed rule and the need for a balanced approach that considers the concerns and perspectives of all involved parties.

Proposed Intervention

The proposed intervention aims to address the pervasive issue of prescription medication non-adherence by introducing a comprehensive and standardized system for providing PMI. The objective is to ensure that all human prescription drug products used on an outpatient basis, including blood and blood components transfused in an outpatient setting, come with accessible and easy-to-understand information. This information, housed in a publicly accessible online repository, is designated as a public good with a zero marginal cost for access. The primary goal is to enhance patient knowledge, adherence, and safe use of prescription drugs by setting specific format, content, readability, and comprehension requirements for PMI. To achieve this, the FDA proposes a five-year staggered implementation timeline, requiring manufacturers to submit PMI based on whether their drugs currently have a Medication Guide or Patient Package Insert (PPI) or are under review. The proposal represents a systemic shift toward improving the quality of information provided to patients, addressing the existing market failures in prescription drug information dissemination. By establishing a standardized and easily accessible source of information, the FDA intends to optimize social welfare, mitigate adverse health outcomes, and reduce healthcare costs associated with prescription medication non-adherence. The intervention reflects a proactive approach to promoting public health and safety by leveraging regulatory mechanisms to enhance the effectiveness of prescription drug use.

Data and Data Collection Methods

The FDA's approach to data collection for the analysis of PMI reflects a nuanced and comprehensive strategy that draws upon diverse sources to ensure a thorough understanding of the pharmaceutical landscape. The Orange Book, a cornerstone in this process, provides a wealth of information regarding prescription New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) products. By tapping into this authoritative source, the FDA identifies a vast array of unique drug products, enabling a detailed examination of the pharmaceutical market. The Purple Book, dedicated to therapeutic biologics, further enriches the dataset by offering insights into products regulated by both the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). This dual-sourced approach ensures a comprehensive coverage of pharmaceuticals, spanning both traditional small molecule drugs and innovative biologics.

In addition to these regulatory databases, the FDA leverages the wealth of information contained in the annual PDUFA Performance Reports. These reports serve as historical archives, documenting past trends in New Drug Application (NDA) and Biologic License Application (BLA) submissions. By analyzing historical averages, the FDA gains valuable insights into submission patterns over time, allowing for informed estimations about future submissions. This forward-looking approach is crucial for anticipating the evolving landscape of pharmaceutical products and adapting regulatory strategies accordingly.

The FDA's reliance on estimations is a pragmatic response to the inherent uncertainties in data availability and industry dynamics. For instance, the adjustment made to the upper bound for prescription NDA products, accounting for outpatient distribution, reflects an understanding of the complex factors influencing pharmaceutical usage patterns. Estimations not only bridge gaps in available data but also allow for flexibility in forecasting, acknowledging the dynamic nature of the pharmaceutical industry where trends can evolve rapidly.

In essence, the data collection methods employed by the FDA for PMI analysis create a robust framework that combines the regulatory rigor of databases with the historical context provided by annual reports and the adaptability offered by estimations. This multifaceted approach ensures that the regulatory decisions regarding PMI implementation are well-informed, accommodating the diverse and dynamic nature of the pharmaceutical landscape.

The FDA identified 2,640 unique prescription New Drug Application (NDA) products as of May 2018, providing a foundational understanding of the market scope. The Purple Book contributed an additional 185 therapeutic biologics regulated by the Center for Drug Evaluation and Research (CDER) and 215 biologics identified by the Center for Biologics Evaluation and Research (CBER) as of January 2020, expanding the dataset to include innovative biologic drugs. The inclusion of blood and blood component products intended for outpatient transfusion further adds granularity to the dataset. The annual PDUFA Performance Reports contribute historical data, enabling insights into submission patterns and trends, crucial for forecasting future PMI submissions. The data collected not only encompasses a wide range of prescription drug products but also reflects a forward-looking perspective, anticipating the evolving landscape of pharmaceutical submissions and facilitating well-informed regulatory decision-making regarding PMI implementation.

Alternative Solutions and Interventions

In the realm of regulatory interventions concerning PMI, alternative solutions must be carefully considered to strike a balance between enhancing the quality of information and managing associated costs. One alternative approach involves implementing a comprehensive consumer testing protocol for PMI. Under this solution, pharmaceutical companies would be required to subject their PMI to qualitative and quantitative testing through focus groups before submission to the FDA. The primary goal of consumer testing is to ensure that the information is not only accurate but also presented in a manner that is easily understandable and comprehensible to the diverse population of patients. While this alternative presents potential benefits in terms of improved readability and comprehension, it introduces an additional layer of costs. The expenses associated with conducting consumer testing, estimated at $107,580 per reference PMI, need to be carefully weighed against the anticipated gains in terms of enhanced patient understanding and potential time savings.

Another alternative solution focuses on a targeted approach, requiring PMI only for high-risk products that currently have Medication Guides or Patient Package Inserts (PPI). This approach recognizes that not all medications carry the same level of risk, and thus, resources can be strategically allocated to those products deemed most critical. By limiting the scope to medications with existing regulatory requirements, the burden on pharmaceutical companies is reduced, leading to potential cost savings. However, this alternative may raise concerns about the comprehensiveness of information coverage, leaving patients without PMI for certain medications. Striking the right balance between targeted risk mitigation and ensuring broad access to essential information is a key consideration in evaluating this alternative.

In evaluating these alternative solutions, it is essential to recognize the diverse perspectives and interests of stakeholders, including patients, healthcare providers, pharmaceutical companies, and medical insurance providers. Patient-centricity is paramount,

with a focus on improving health outcomes through enhanced understanding of medication information. Healthcare providers, on the other hand, seek solutions that streamline their interactions with patients while ensuring optimal care. Pharmaceutical companies navigate the challenge of compliance costs and maintaining efficient operations, while medical insurance companies are concerned with the broader economic implications, including potential impacts on drug pricing and overall healthcare utilization. The ultimate choice among these alternative solutions requires a nuanced consideration of these perspectives, weighing the costs and benefits in a manner that aligns with overarching healthcare goals and principles.

Cost Benefit Analysis for PMI

The potential benefits of the proposed rule of PMI are that patients will benefit from reduced search costs for medical information. Another benefit is the reduction in risk associated with drug products, providing patients with clear, concise, and useful written information about the medical product being administered in outpatient settings. This rule may impact the current consumer medication (CMI) and patient package inserts (PPI's) that usually provide unclear information on medical products. The proposed rule can negatively impact competitors as they may be forced to revise their patient information plans, potentially incurring additional costs or moving away from their format altogether due to the efficiency of PMI. This is a possible unintended consequence, but there is also monetary value that competitors can gain, which we will explore when explaining the value of the proposed rule. Another benefit of PMI is that it will be stored in online databases available to the public, improving consumers' knowledge of medication. A possible unintended consequence could be the discontinuation of certain cheaper medications that aren't worth spending money to create a PMI for.

We reviewed how this plan will provide monetary benefit; the monetary is the reduction of search costs, estimating the average annualized net cost to be $127.5 million over 10 years. Also, the net cost of $4.3 billion using a 3 percent discount rate with the primary estimate of $1.6 billion. The primary benefits of PMI would range $101.0 million and $4.3 billion, with a primary estimate of $1.3 billion. Over a 10-year evaluation, the estimated benefit ranges between $14.9 and $507.9 million. This will also result in a primary estimate of $180.5 million per year. When PMI replaces other medical guides, they can potentially gain monetary benefits from this proposal because they will save money since they will not need to submit and update medical guides regularly.

Equity and Efficiency

PMI will create an equitable atmosphere in the medical field by providing the public with adequate information on medical products. The fact that PMI will be stored in national databases for the public gives everyone a chance to review medical information and make the right choice with information that is easily digestible to patients. This will reduce mistakes in the medical field, including pharmacists accidentally administering the wrong medicine to patients. Although this mistake is still possible with PMI, patients will have the knowledge to correct the mistake made by the pharmacies. The efficiency of this depends greatly on PMI having information that all patients can understand. This is vital to the success of the proposed plan because the reason for the plan, in the first place, is to provide patients with medical information on medical products. The online database will be easily accessible to the public so that patients can easily navigate and find information on their medication. This database should be accessible to the

public 24 hours a day; this will not only be convenient to patients but will also create an efficient source where patients can access their medical information at any time.

Unintended Consequences

The implementation of regulatory interventions can have a range of unintended consequences, some of which may impact market competition within the pharmaceutical industry. One potential consequence is an increased barrier to entry for smaller pharmaceutical companies or new market entrants. The costs associated with developing, submitting, and consumer-testing PMI, as proposed in one alternative, may disproportionately affect smaller players, potentially limiting their ability to bring new medications to market. This could inadvertently consolidate market power among larger pharmaceutical companies that have the financial resources to navigate the regulatory landscape. Additionally, the focus on high-risk products, as suggested by another alternative, may create a scenario where certain medications, particularly those deemed lower risk but still essential, receive less regulatory attention. This selective approach could influence market dynamics, potentially favoring high-risk medications and altering the competitive landscape based on regulatory requirements rather than the inherent risk or therapeutic value of a drug. It is crucial for regulators to carefully assess the potential unintended consequences on competition and take measures to ensure that regulatory interventions do not inadvertently stifle innovation, limit market diversity, or create imbalances that may disadvantage certain segments of the pharmaceutical industry. Striking a balance between regulatory safeguards and fostering a competitive environment is essential to promote innovation, ensure a variety of treatment options, and maintain a healthy pharmaceutical market.

References

Medication guides: Patient medication information - U.S. food and drug ... (n.d.-b). https://www.fda.gov/media/169303/download?attachment